The KITD816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease
Citations Over TimeTop 10% of 2014 papers
Abstract
KIT D816V is present in a majority of patients with systemic mastocytosis (SM). We determined the KIT D816V allele burden by quantitative real-time PCR in bone marrow and peripheral blood of 105 patients with mastocytosis. KIT D816V was detected in 92/105 patients (88%). Significant differences in the median allele burden were observed between disease subgroups: cutaneous mastocytosis (0.042%), indolent SM (0.285%), smoldering SM (5.991%), aggressive SM (9.346%), and SM with associated hematologic non-mast cell lineage disease (3.761%) (P < 0.001). The KIT D816V burden also correlated with serum tryptase (R = 0.5, P < 0.005) but not with mast cell infiltration in bone marrow or mediator symptoms. Moreover, the allele burden was of prognostic significance regarding survival (P < 0.01). Patients responding to cytoreductive therapy showed a significant decrease in KIT D816V (P < 0.05). To conclude, the KIT D816V burden correlates with the variant of mastocytosis, predicts survival, and is a valuable follow-up parameter in SM.
Related Papers
- → A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis(2017)92 cited
- → Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis(2018)44 cited
- → Biochemical Diagnosis of Systemic Mast Cell Disorders(1991)74 cited
- → The Role of Avapritinib for the Treatment of Systemic Mastocytosis(2021)3 cited
- → Mastocytosis(2011)